In this photo illustration, the Kenvue company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Anan Ashraf·Stocktwits

Updated Jul 02, 2025 | 8:31 PM GMT-04

Share this article

Shares of Kenvue Inc. (NYSE: KVUE) traded 6% higher on Thursday morning after the company announced upbeat first-quarter earnings and appointed a new CFO.

The consumer health company’s net sales decreased 3.9% year-on-year to $3.74 billion, but topped an analyst estimate of $3.68 billion, per Finchat data.

Net sales fell across its self-care, skin health, beauty, and essential health segments. However, the company’s skin health and beauty segment declined by 7% to $977 million.

Adjusted diluted earnings per share (EPS) came in at $0.24, compared to $0.28 in the prior year period, and above an analyst estimate of $0.23.

The BAND-AID, Listerine, and Neutrogena brand parent also updated its full-year 2025 outlook to reflect current foreign exchange rates and the estimated impact of higher costs due to U.S. tariffs.

The company now expects a full-year net sales increase of 1% to 3% year over year, above a previous estimate of -1% to 1%.

However, it estimates adjusted diluted earnings per share to be about flat compared to FY24, when it reported a profit of $1.14 per share. The company had previously estimated flat to 2% year-over-year EPS growth.

The company said the new EPS guidance includes a low-single-digit unfavorable impact from foreign currency.

Kenvue also said it is working on reducing the financial impact of tariffs through numerous mitigation measures.

Separately, the firm also announced that it has appointed Amit Banati as its new CFO, effective May 12. Banati, who served most recently as Vice Chairman and CFO of Kellanova, will succeed Paul Ruh.

On Stocktwits, retail sentiment around Kenvue stayed unmoved within the ‘neutral’ territory over the past 24 hours while message volume jumped from ‘normal’ to ‘high’ levels.